EW
ABCL icon

Evoke Wealth’s AbCellera Biologics ABCL Stock Holding History

Evoke Wealth’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,200
Closed -$12K – 1157
2022
Q1 		$12K Hold
1,200
– – ﹤0.01% 731
2021
Q4 		$17K Sell
1,200
-1,785
-60% -$27.1K ﹤0.01% 699
2021
Q3 		$59K Buy
2,985
+2,200
+280% +$38.9K ﹤0.01% 490
2021
Q2 		$17K Hold
785
– – ﹤0.01% 673
2021
Q1 		$27K Buy
+785
New +$31.3K ﹤0.01% 532

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Evoke Wealth's ABCL Position: Q2 2022 in Review

Evoke Wealth sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 1,200 shares — an estimated $12K sold.

Evoke Wealth first reported a position in ABCL in Q1 2021 and held it in 5 quarters. The position peaked at $59K in Q3 2021. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • Evoke Wealth reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • Evoke Wealth sold 1,200 AbCellera Biologics shares in Q2 2022, an estimated $12K.
  • Evoke Wealth first reported a position in AbCellera Biologics in Q1 2021 and held it in 5 quarters.
  • Evoke Wealth's AbCellera Biologics position peaked at $59K in Q3 2021.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.